Native IBV (B/Brisbane/33/08) Antigen

Name: Native IBV (B/Brisbane/33/08) Antigen
SKU: DAGC482
Rating: 5 (1 reviews)

Native IBV (B/Brisbane/33/08) Antigen from MDCK Cells

COA

SDS

Datasheet

Summary

Product Overview

Influenza virus is propagated in the MDCK cell line. Virus is purified using sucrose density gradient ultracentrifugation, disrupted in the presence of 0.5% Triton X-100 non-ionic detergent/0.6 M KCl, and heat inactivated.

Nature

Native

Tag/Conjugate

Unconjugated

Alternative Names

IBV; Influenza B virus; Influenza B

Format

Liquid

Buffer

0.5% Triton X-100 non-ionic detergent/0.6 M KCl

Preservative

None

Storage

Store at -80°C.

Introduction

The influenza B virus is the only species of virus in the genus Betainfluenzavirus within the family Orthomyxoviridae. Influenza B viruses have linear, negative-sense, single-stranded multipartite RNA genomes. The Influenza B virus capsid is enveloped and its virion comprises an envelope protein, matrix protein, nucleoprotein complex, a nucleocapsid, and polymerase complex. Influenza viruses are highly pleomorphic, with 500 or so surface projections of Hemagglutinin (HA) and Neuraminidase (NA). Unlike influenza A viruses, influenza B viruses are limited to infecting only humans and seals and can be divided into the two B/Yamagata/16/88-like and B/Victoria/2/87 lineages according to the antigenic properties of their Haemagglutinin surface proteins. The limited host range of influenza B viruses and their inability to genetically reassort is responsible for the lack of associated influenza pandemics in contrast with those caused by related influenza A viruses that mutate by both antigenic drift and shift. The variability of the type B viruses, however, is also characterised by other mechanisms such as insertion and deletion, as the influenza B lines show which have been co-circulating and stable for more than 20 years. The B/Brisbane/33/2008 strain of influenza B virus was first isolated in 2008 in Brisbane, Australia. The strain was formulated in subsequent multi-valent flu vaccines from 2009-2010.

Keywords

IBV; Influenza B virus; Influenza B

Citations

Have you cited DAGC482 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Influenza Virus Antigens

QA & Reviews

Customer Reviews

References

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

MICROBIAL PATHOGENESIS

Authors: Matoo, Javaid Jeelani; Bashir, Khalid; Kumar, Ajay; Krishnaswamy, Narayanan; Dey, Sohini; Chellappa, Madhan Mohan; Ramakrishnan, Saravanan

Abstract

Adjuvant enhancing mucosal immune response is preferred in controlling many pathogens at the portal of entry. Earlier, we reported that a toll-like-receptor 7 (TLR7) agonist, resiquimod (R-848), stimulated the systemic immunity when adjuvanted with the inactivated Newcastle disease virus vaccine in the chicken. Here, we report the effect of R-848 when adjuvanted with live or inactivated avian infectious bronchitis virus (IBV) vaccines with special emphasis on mucosal immunity. Specific pathogen free (SPF) chicks (n = 60) were equally divided into six groups at two weeks of age and immunized with either inactivated or live IBV vaccine adjuvanted with or without R-848. Groups that received either PBS or R-848 served as control. A booster was given on 14 days post-immunization (dpi). R-848 enhanced the antigen specific humoral and cellular immune responses when co-administered with the vaccines as evidenced by an increase in the antibody titre in ELISA and stimulation index in lymphocyte transformation test (LTT) till 35 dpi and increased proportion of CD4(+) and CD8(+) T cells on 21 dpi in the flow cytometry. Interestingly, it potentiated the IgA responses in the tear and intestinal secretions when used with both live and inactivated IBV vaccines. The combination of IBV vaccine with R-848 significantly up-regulated the transforming growth factor beta 4 (TGF beta 34) transcripts in the peripheral blood mononuclear cells (PBMCs) than that of the respective vaccine per se. An enhanced secretory IgA response is likely due to the up-regulation of TGF beta 4, which is responsible for class switching to IgA. In conclusion, co-administration of R-848 with inactivated or live IBV vaccine enhanced the systemic as well as mucosal immune responses in the chicken.

Vaccination against infectious bronchitis virus: A continuous challenge

VETERINARY MICROBIOLOGY

Authors: Jordan, Brian

Abstract

Infectious bronchitis virus (IBV) is a significant respiratory pathogen of commercial poultry that causes millions of dollars in lost revenue worldwide each year. Even though the poultry industry extensively vaccinates against IBV, emergence of new serotypes and variants continually occur, making control of the disease difficult. Current mass application strategies for IBV vaccines are inefficient and frequently result in vaccination failures. Novel vaccine technology development has been slow, and is hindered by the constraints of large-scale poultry production. Further complicating the situation is the lack of knowledge of IBV protein and host cell interactions, making targeted vaccine intervention strategies near impossible. Taken together, it is easy to see why this disease remains significant in poultry production. This review outlines the current situation as it relates to IBV control, including vaccination, vaccines, and development of immunity, and recent developments in vaccine technology that may provide better protection in the future. (C) 2017 Elsevier B.V. All rights reserved.